Introduction
============

Therapies that target vascular endothelial growth factor (VEGF) have revolutionized the treatment of neovascular (or wet) age-related macular degeneration (nAMD) and have become the standard of care for this condition.[@b1-opth-9-1315]

Ranibizumab (Lucentis^®^; Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc., South San Francisco, CA, USA), a recombinant, humanized anti-VEGF Fab fragment that neutralizes all forms of VEGF-A,[@b2-opth-9-1315] was approved for intravitreal use to treat nAMD by the Food and Drug Administration (FDA) in 2006.[@b3-opth-9-1315] According to the European summary of product characteristics, patients can be given monthly injections until maximal visual acuity (VA) is achieved, followed by flexible dosing, where treatment and monitoring intervals are based on disease activity as assessed by VA and/or anatomical parameters visualized using optical coherence tomography (OCT) or other appropriate imaging modalities.[@b3-opth-9-1315]

Bevacizumab (Avastin^®^; Genentech, Inc., South San Francisco, CA, USA, a member of the Roche group) is also used to treat nAMD; however, this drug is not licensed for nAMD, and its use is off-label. Bevacizumab is a humanized monoclonal anti-VEGF antibody that was initially designed as an anti-angiogenesis inhibitor to treat metastatic colorectal cancer.[@b4-opth-9-1315],[@b5-opth-9-1315]

Aflibercept (Eylea^®^; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, and Bayer AG, Berlin, Germany) is a soluble recombinant fusion protein, which is made up of portions of the human VEGF receptor fused to the Fc portion of human IgG1,[@b6-opth-9-1315] and binds to VEGF-A, VEGF-B, and placental growth factor.[@b7-opth-9-1315] In 2011, aflibercept was approved by the FDA for nAMD,[@b8-opth-9-1315] with the current approved treatment regimen for aflibercept consisting of three initial 2 mg monthly injections followed by 8-weekly dosing.[@b8-opth-9-1315],[@b9-opth-9-1315]

When faced with a patient with nAMD, the ophthalmologist therefore has three potential anti-VEGF therapies to choose from: ranibizumab, bevacizumab, and aflibercept. The decision on which anti-VEGF to treat patients with is multifactorial and factors include availability, dosing schedule, recent trial data on efficacy and safety, and cost.[@b10-opth-9-1315] Based on the efficacy data from the VIEW trial, we decided to start fixed bimonthly aflibercept treatment in some of our patients in accordance with the product label. This study reports our early experience with these patients and was conducted to assess whether the response to fixed 8-weekly aflibercept treatment was beneficial in all treatment-experienced patients with nAMD.

Patients and methods
====================

Study design
------------

This was a consecutive, retrospective, observational study to assess visual outcomes in treatment-experienced patients with nAMD who were treated with aflibercept in accordance with the drug label. The study was conducted in a single center in the USA between December 2011 and November 2013. To be included in the study, patients must have been diagnosed with nAMD and received three consecutive monthly loading doses of aflibercept 2.0 mg (Visits 1--3), in accordance with the product label, and a follow-up visit with an average of 6.8 weeks after the monthly dosing (Visit 4). In addition, all the patients must have received one or more previous treatments of ranibizumab 0.5 mg or bevacizumab 1.25 mg. Patients who did not receive the three loading doses of aflibercept were excluded from the study.

Diagnosis
---------

Neovascular AMD was diagnosed by fundoscopy, OCT, and fluorescein angiography.

Outcome measures
----------------

### Patient demographics

Demographic data were collected and included age, sex, ethnicity, treated eye, number of previous ranibizumab and/or bevacizumab injections, time between injections, and response to treatment as determined by OCT and best-corrected visual acuity (BCVA).

### OCT outcomes

Central macular thickness (CMT) was recorded at baseline and at each visit. The presence of pigment epithelial detachment (PED) or intra- or subretinal fluid (IRF and SRF, respectively) on OCT was also recorded at baseline and at each visit.

### VA

BCVA was assessed using the Snellen scale at each visit. VA data were converted to approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters using the method reported by Gregori et al.[@b11-opth-9-1315]

Ethics statement
----------------

Due to the retrospective nature of this study, it received exempt approval from the Western Institutional Review Board. Accordingly, patient information was anonymized and de-identified before analysis. Research was carried out in accordance with the Declaration of Helsinki.

Results
=======

A total of 16 eyes from 16 patients met the inclusion criteria. Baseline patient demographics are shown in [Table 1](#t1-opth-9-1315){ref-type="table"}. The mean age of the patients was 75 years (range: 63--88 years). All of the patients were Caucasian, and the majority (12; 75%) was women. Equal numbers of right and left eyes were treated. The patients received a mean of 9.4 injections (range: 2--19) of either bevacizumab, ranibizumab, or a combination of both before aflibercept treatment. Following the initial three monthly aflibercept injections, the patients received a follow-up assessment with an average of 6.8 weeks after the third injection.

BCVA
----

The mean BCVA at baseline (Visit 1) was 62 approximate ETDRS letters (range: 0--85 approximate ETDRS letters) ([Table 2](#t2-opth-9-1315){ref-type="table"}). At the end of the monthly dosing period, nine patients (56%) had improved BCVA and seven patients (44%) had stable or decreased BCVA. Mean BCVA at month 3 was 67 approximate ETDRS letters. However, between Visit 3 and Visit 4, seven patients (44%) had decreased VA, and the mean BCVA at Visit 4 was 63 approximate ETDRS letters. This meant that there was an overall mean loss of four approximate ETDRS letters between Visit 3 and Visit 4.

CMT
---

[Table 3](#t3-opth-9-1315){ref-type="table"} summarizes the CMT measurements across the study period. CMT at baseline ranged from 244 to 571 μm, with a mean of 367 μm. Following the three initial monthly doses, there were improvements in CMT in 13 patients (87%). The mean reduction in CMT from baseline to Visit 3 was 76 μm. Between Visit 3 and Visit 4, there was a mean increase in CMT of 54.4 μm (range: −32--383 μm).

PED
---

PED was observed in four patients at baseline (Visit 1). Following the initial monthly dosing, PED improved in three patients and enlarged in one patient. However, by Visit 4, PED was apparent in all the four patients ([Table 4](#t4-opth-9-1315){ref-type="table"}).

IRF and SRF
-----------

All 16 patients presented with fluid at baseline (Visit 1) on OCT ([Table 3](#t3-opth-9-1315){ref-type="table"} and [Figure 1](#f1-opth-9-1315){ref-type="fig"}). IRF, including intraretinal cysts, was present in five patients (31%), and SRF was present in 13 patients (81%). Following the initial three monthly aflibercept injections, ten patients (77%) had improved SRF and two out of five patients (40%) had improved IRF. At the fourth visit, SRF had increased in nine out of 13 patients (69%), existing IRF was increased in three out of five patients (60%), and new IRF had developed in one out of 16 patients (6.3%). Fluid remained in 12 out of 16 patients (75%).

Based on the presence of IRF and SRF described earlier, the majority of patients (75%) had recurrent fluid and could not be extended to dosing every 8 weeks ([Table 3](#t3-opth-9-1315){ref-type="table"}).

Discussion
==========

This study reports our clinical experience using fixed bimonthly aflibercept in treatment-experienced patients with nAMD. Overall, there were anatomical (SRF and/or IRF) and visual improvements following the initial three monthly aflibercept injections in 12 patients (75%) and nine patients (56%), respectively; however, when the dosing interval was extended, BCVA decreased in seven patients (44%) and fluid increased in 12 patients (75%). Only four patients (25%) could be extended to dosing every 8 weeks based on fluid on OCT. These findings suggest that the fixed 8-weekly dosing schedule may not be optimal for all treatment-experienced patients in clinical practice. This is an important consideration for ophthalmologists as the aflibercept product label mandates 8-weekly dosing in the first year of treatment for nAMD.[@b8-opth-9-1315]

While 8-weekly injections have several potential benefits over monthly injections and monitoring, including fewer visits for patients and fewer ocular injections, a careful balance must be struck to maintain any gains achieved with monthly dosing. Data from the pivotal VIEW trials showed that 8-weekly aflibercept dosing following three initial monthly injections was noninferior to monthly ranibizumab dosing at week 52.[@b12-opth-9-1315] In addition, at week 52, patients treated with 8-weekly aflibercept had reductions in central retinal thickness that were similar to the reductions experienced by patients treated with monthly ranibizumab, although fluctuations were observed in the 8-weekly aflibercept treatment group.[@b12-opth-9-1315] In line with the VIEW data, a recent, small (n=26), single-arm, prospective study of fixed 8-weekly dosing of aflibercept in treatment-experienced patients showed functional anatomical improvements with aflibercept after 6 months.[@b13-opth-9-1315]

Based on the VIEW study data described above and the approved product label,[@b8-opth-9-1315],[@b12-opth-9-1315] we expected a maintenance or improvement of visual and anatomical outcomes with this fixed dosing schedule; however, this is not what we observed. The results of our study, which included patients from our clinic who received aflibercept treatment in the expectation of achieving an 8-weekly dosing schedule, suggest that the duration of action of aflibercept may be \<8 weeks in a meaningful proportion of patients. This aligns with the fluctuations in central retinal thickness observed in the 8-weekly aflibercept group in the VIEW study.[@b12-opth-9-1315]

Several other small-scale retrospective studies and chart reviews investigating aflibercept treatment in real-life clinical practice have also recently been performed; however, the results from these studies vary.[@b14-opth-9-1315]--[@b20-opth-9-1315] Collectively however, the results provide ophthalmologists with valuable information to consider when deciding the best treatment options for their patients.

Limitations of our study include the single-arm retrospective design, the relatively small number of cases, the lack of controls, and the fact that our observations are limited to the visits after only four injections of aflibercept. However, our data do suggest that patients respond differently to treatment and fixed dosing may therefore be suboptimal, leaving some patients under- or overtreated. If this is the case, there may be a subsequent impact on health care providers expecting to provide aflibercept according to a fixed 8-weekly regimen if many patients require more frequent injections (ie, \<8 weeks apart) in terms of clinic organization and visit scheduling, as well as potential implications for the comparative cost-effectiveness of aflibercept and other anti-VEGF agents. Our findings should therefore be further investigated in studies of aflibercept use in clinical practice and randomized controlled trials of different aflibercept dosing schedules. Existing data from recent studies with anti-VEGF agents suggest the benefits of flexible dosing regimens. The efficacy of a pro re nata (PRN; as needed) regimen with monthly monitoring has been confirmed in the HARBOR trial, where patients required a mean of 7.7 injections during the first year of treatment, including the initial three injections,[@b21-opth-9-1315] while the CATT study illustrated that equivalent improvements in VA were observed with both monthly and PRN ranibizumab dosing after 2 years of treatment.[@b22-opth-9-1315] Furthermore, treat-and-extend regimens that have the potential to reduce clinic burden are increasingly being investigated, with a recent prospective study achieving visual outcomes after 12 and 24 months that were comparable with the pivotal ranibizumab trials (ANCHOR and MARINA), but with fewer injections and clinic visits.[@b23-opth-9-1315]

Overall, our data add to the growing body of evidence indicating that fixed-dose regimens are not suitable for all patients with nAMD and highlight a need for flexible dosing schedules with treatment and monitoring intervals based on disease activity.
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###### 

Patient demographics

  Eye no   Age (years)   Sex   Eye   Previous BEV (n)   Previous RBZ (n)   Total BEV and RBZ (n)
  -------- ------------- ----- ----- ------------------ ------------------ -----------------------
  1        71            F     OS    14                 4                  18
  2        75            F     OD    7                  4                  11
  3        80            F     OS    9                  3                  12
  4        66            F     OD    8                  9                  17
  5        66            M     OD    5                  0                  5
  6        69            F     OD    5                  0                  5
  7        63            F     OS    13                 6                  19
  8        80            F     OD    2                  0                  2
  9        82            M     OS    0                  9                  9
  10       85            M     OS    8                  0                  8
  11       87            F     OS    4                  3                  7
  12       73            F     OS    0                  5                  5
  13       67            F     OD    10                 1                  11
  14       77            F     OD    5                  4                  9
  15       88            M     OD    0                  3                  3
  16       71            F     OS    5                  5                  10
  Mean     75                        5.9                3.5                9.4

**Abbreviations:** no, number; BEV, bevacizumab; RBZ, ranibizumab; n, number of injections; F, female; M, male; OD, oculus dexter; OS, oculus sinister.

###### 

Changes in BCVA in 16 patients treated with fixed aflibercept dosing[a](#tfn2-opth-9-1315){ref-type="table-fn"}

  Eye no   BCVA Visit 1                                   BCVA change Visits 1--3                        BCVA change Visits 1--4                        BCVA change Visits 3--4
  -------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- -----------------------------------------------
  1        65                                             5                                              0                                              −5
  2        80                                             0                                              0                                              0
  3        80                                             0                                              0                                              0
  4        85                                             −5                                             −5                                             0
  5        80                                             −10                                            −4                                             6
  6        50                                             8                                              −15                                            −23
  7        65                                             15                                             −4                                             −19
  8        58                                             22                                             12                                             −10
  9        55                                             −20                                            −5                                             15
  10       70                                             6                                              6                                              0
  11       58                                             3                                              3                                              0
  12       65                                             5                                              −15                                            −20
  13       35                                             23                                             23                                             0
  14       65                                             0[b](#tfn3-opth-9-1315){ref-type="table-fn"}   11                                             11
  15       0[b](#tfn3-opth-9-1315){ref-type="table-fn"}   35                                             26                                             −9
  16       76                                             −6                                             −11                                            −5
  Mean     62                                             5[c](#tfn4-opth-9-1315){ref-type="table-fn"}   1[c](#tfn4-opth-9-1315){ref-type="table-fn"}   −4[c](#tfn4-opth-9-1315){ref-type="table-fn"}

**Notes:**

Patients received three monthly injections of aflibercept at Visits 1--3 and were followed up for 4--10 weeks after the third injection.

Classed as counting two fingers at 2 feet.

Mean change reported.

**Abbreviations:** BCVA, best-corrected visual acuity (approximate ETDRS letters); no, number; ETDRS, Early Treatment Diabetic Retinopathy Study.

###### 

Changes in CMT (μm) and fluid observations in 16 patients treated with fixed aflibercept dosing[a](#tfn6-opth-9-1315){ref-type="table-fn"}

  Eye no   Fluid Visit 1      Fluid Visit 3                 Fluid Visit 4                 Responder/nonresponder[b](#tfn7-opth-9-1315){ref-type="table-fn"}   CMT Visit 1 (µm)   CMT Visits 1--3 (µm)                             CMT Visits 1--4 (µm)                             CMT Visits 3--4 (µm)
  -------- ------------------ ----------------------------- ----------------------------- ------------------------------------------------------------------- ------------------ ------------------------------------------------ ------------------------------------------------ -------------------------------------------------
  1        +SRF, +SR scar     SRF                           +SRF                          NR                                                                  328                −29                                              −23                                              6
  2        +SRF               SRF                           +SRF                          NR                                                                  281                −8                                               −10                                              −2
  3        +SRF               SRF                           +SRF                          NR                                                                  417                −102                                             −103                                             −1
  4        +SRF, +PED         No SRF, minimal PED           +SRF, +IRF, +PED              NR                                                                  283                −48                                              71                                               119
  5        +SRF               Increased SRF                 +SRF                          NR                                                                  360                −51                                              −23                                              28
  6        +SRF, +PED         No fluid, stable PED          +SRF, +PED                    NR                                                                  326                −28                                              40                                               68
  7        Diffuse IRF        Persistent IR cysts           +IR cysts                     NR                                                                  433                −123                                             47                                               170
  8        +SRF, +PED         No SRF, minimal PED           +SRF, large PED               NR                                                                  571                −345                                             38                                               383
  9        +SRF, +SR scar     SRF, SR scar                  +SRF, +SR scar                NR                                                                  473                NA                                               NA                                               NA
  10       +IR cysts          No fluid                      +IR cysts                     NR                                                                  346                −50                                              −31                                              19
  11       +SRF, +PED, +IRF   Enlarged PED, increased IRF   Enlarged PED, increased IRF   NR                                                                  557                −201                                             −119                                             82
  12       +SRF               Persistent SRF                Increased SRF                 NR                                                                  312                9                                                −12                                              −21
  13       +SRF               No fluid                      No fluid                      R                                                                   390                −170                                             −164                                             6
  14       +SRF               No fluid                      No fluid                      R                                                                   272                −10                                              −8                                               2
  15       IRF                IR cysts                      No fluid                      R                                                                   244                32                                               0                                                −32
  16       +IRF, +SRF         SRF                           No fluid                      R                                                                   276                −21                                              −32                                              −11
  Mean                                                                                                                                                        367                −76[c](#tfn8-opth-9-1315){ref-type="table-fn"}   −22[c](#tfn8-opth-9-1315){ref-type="table-fn"}   54.4[c](#tfn8-opth-9-1315){ref-type="table-fn"}

**Notes:**

Patients received three initial monthly injections of aflibercept at Visits 1--3 and were followed up 4--10 weeks after the third injection.

According to the presence of fluid on OCT.

Mean change reported.

**Abbreviations:** CMT, central macular thickness; no, number; SRF, subretinal fluid; PED, pigment epithelial detachment; IRF, intraretinal fluid; R, responder; NR, nonresponder; NA, data not available; OCT, optical coherence tomography.

###### 

PED measurements (μm) at Visits 1--4

  Eye no   Visit 1 H/W   Visit 2 H/W   Visit 3 H/W   Visit 4 H/W
  -------- ------------- ------------- ------------- -------------
  4        256/3,135     92/3,089      78/3,009      138/3,175
  6        428/1,916     324/2,080     115/2,015     565/2,198
  8        133/1,776     90/1,934      111/1,817     170/1,975
  11       172/1,797     73/1,800      212/2,374     209/2,366

**Abbreviations:** PED, pigment epithelial detachment; no, number; H, height; W, width.
